Global Biolistic Particle Delivery System Market

Biolistic Particle Delivery System Comprehensive Study by Application (Genetic vaccination, Cancer gene therapy, Immunomodulation, Genetic pharmacology, Others), Modality (Portable, Fixed), End User (Hospitals, Genetic Research Institutes, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2027

Biolistic Particle Delivery System Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Biolistic Particle Delivery System Market?

A biolistic particle delivery system is used to transmit genetic information to cells by administering specific RNA or DNA. RNA or DNA is coated over a transporter, which may be an elemental particle of heavy metal, and released with high-velocity acceleration to perforate the cell membrane in a biolistic particle delivery device. This genetic knowledge from plasmid DNA is then used to turn target tissue to achieve the desired effects. As a result, the biolistic particle delivery mechanism plays a critical role in altering the cell's genetic structure by adding foreign material. The biolistic particle delivery system is not only used in humans, but also in plants and animals where drought tolerance genes are added.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledBio-Rad Laboratories, Inc. (United States), Chintek Technology Co., Ltd. (Taiwan), Thermo Fisher Scientific, Inc., Wealtech Corporation, Life Technologies Corporation (United States), Harvard Bioscience, Inc., DuPont de Nemours, Inc. (United States), Ningbo Scientz Biotechnology Co., Ltd. (China) and Biotechnologies, Inc. (India)


The market study is being classified, by Application (Genetic vaccination, Cancer gene therapy, Immunomodulation, Genetic pharmacology and Others) and major geographies with country level break-up..

Bio-Rad Laboratories, Inc. (United States), Chintek Technology Co., Ltd. (Taiwan), Thermo Fisher Scientific, Inc., Wealtech Corporation, Life Technologies Corporation (United States), Harvard Bioscience, Inc., DuPont de Nemours, Inc. (United States), Ningbo Scientz Biotechnology Co., Ltd. (China) and Biotechnologies, Inc. (India) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Biolistic Particle Delivery System market throughout the forecasted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Biolistic Particle Delivery System market by Type, Application and Region.

On the basis of geography, the market of Biolistic Particle Delivery System has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rise in the Prevalence of Genetic Disorders
  • Increasing Awareness and Treatment-seeking Rate for Gene Therapy

Market Trend
  • Advancements in the Field of Genetic Engineering

Restraints
  • Ethical Issues related to Gene Alteration

Opportunities
  • Increase in Research and Development Activities for Genomic Medicine
  • Rising Investment by Key Players

Challenges
  • Inaccuracy in the method


In July 2020 Novartis International AG and Sangamo Therapeutics announce collaboration for research and development activities in the field of genomic medicine.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Biolistic Particle Delivery System Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Application
  • Genetic vaccination
  • Cancer gene therapy
  • Immunomodulation
  • Genetic pharmacology
  • Others
By Modality
  • Portable
  • Fixed

By End User
  • Hospitals
  • Genetic Research Institutes
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in the Prevalence of Genetic Disorders
      • 3.2.2. Increasing Awareness and Treatment-seeking Rate for Gene Therapy
    • 3.3. Market Challenges
      • 3.3.1. Inaccuracy in the method
    • 3.4. Market Trends
      • 3.4.1. Advancements in the Field of Genetic Engineering
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biolistic Particle Delivery System, by Application, Modality, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Biolistic Particle Delivery System (Value)
      • 5.2.1. Global Biolistic Particle Delivery System by: Application (Value)
        • 5.2.1.1. Genetic vaccination
        • 5.2.1.2. Cancer gene therapy
        • 5.2.1.3. Immunomodulation
        • 5.2.1.4. Genetic pharmacology
        • 5.2.1.5. Others
      • 5.2.2. Global Biolistic Particle Delivery System by: Modality (Value)
        • 5.2.2.1. Portable
        • 5.2.2.2. Fixed
      • 5.2.3. Global Biolistic Particle Delivery System by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Genetic Research Institutes
        • 5.2.3.3. Specialty Clinics
        • 5.2.3.4. Others
      • 5.2.4. Global Biolistic Particle Delivery System Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Biolistic Particle Delivery System (Price)
  • 6. Biolistic Particle Delivery System: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Chintek Technology Co., Ltd. (Taiwan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific, Inc.
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Wealtech Corporation
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Life Technologies Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Harvard Bioscience, Inc.
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. DuPont de Nemours, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ningbo Scientz Biotechnology Co., Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biotechnologies, Inc. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Biolistic Particle Delivery System Sale, by Application, Modality, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Biolistic Particle Delivery System (Value)
      • 7.2.1. Global Biolistic Particle Delivery System by: Application (Value)
        • 7.2.1.1. Genetic vaccination
        • 7.2.1.2. Cancer gene therapy
        • 7.2.1.3. Immunomodulation
        • 7.2.1.4. Genetic pharmacology
        • 7.2.1.5. Others
      • 7.2.2. Global Biolistic Particle Delivery System by: Modality (Value)
        • 7.2.2.1. Portable
        • 7.2.2.2. Fixed
      • 7.2.3. Global Biolistic Particle Delivery System by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Genetic Research Institutes
        • 7.2.3.3. Specialty Clinics
        • 7.2.3.4. Others
      • 7.2.4. Global Biolistic Particle Delivery System Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Biolistic Particle Delivery System (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biolistic Particle Delivery System: by Application(USD Million)
  • Table 2. Biolistic Particle Delivery System Genetic vaccination , by Region USD Million (2016-2021)
  • Table 3. Biolistic Particle Delivery System Cancer gene therapy , by Region USD Million (2016-2021)
  • Table 4. Biolistic Particle Delivery System Immunomodulation , by Region USD Million (2016-2021)
  • Table 5. Biolistic Particle Delivery System Genetic pharmacology , by Region USD Million (2016-2021)
  • Table 6. Biolistic Particle Delivery System Others , by Region USD Million (2016-2021)
  • Table 7. Biolistic Particle Delivery System: by Modality(USD Million)
  • Table 8. Biolistic Particle Delivery System Portable , by Region USD Million (2016-2021)
  • Table 9. Biolistic Particle Delivery System Fixed , by Region USD Million (2016-2021)
  • Table 10. Biolistic Particle Delivery System: by End User(USD Million)
  • Table 11. Biolistic Particle Delivery System Hospitals , by Region USD Million (2016-2021)
  • Table 12. Biolistic Particle Delivery System Genetic Research Institutes , by Region USD Million (2016-2021)
  • Table 13. Biolistic Particle Delivery System Specialty Clinics , by Region USD Million (2016-2021)
  • Table 14. Biolistic Particle Delivery System Others , by Region USD Million (2016-2021)
  • Table 15. South America Biolistic Particle Delivery System, by Country USD Million (2016-2021)
  • Table 16. South America Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 17. South America Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 18. South America Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 19. Brazil Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 20. Brazil Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 21. Brazil Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 22. Argentina Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 23. Argentina Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 24. Argentina Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 25. Rest of South America Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 26. Rest of South America Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 27. Rest of South America Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 28. Asia Pacific Biolistic Particle Delivery System, by Country USD Million (2016-2021)
  • Table 29. Asia Pacific Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 30. Asia Pacific Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 31. Asia Pacific Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 32. China Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 33. China Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 34. China Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 35. Japan Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 36. Japan Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 37. Japan Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 38. India Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 39. India Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 40. India Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 41. South Korea Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 42. South Korea Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 43. South Korea Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 44. Taiwan Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 45. Taiwan Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 46. Taiwan Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 47. Australia Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 48. Australia Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 49. Australia Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 53. Europe Biolistic Particle Delivery System, by Country USD Million (2016-2021)
  • Table 54. Europe Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 55. Europe Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 56. Europe Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 57. Germany Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 58. Germany Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 59. Germany Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 60. France Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 61. France Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 62. France Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 63. Italy Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 64. Italy Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 65. Italy Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 66. United Kingdom Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 67. United Kingdom Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 68. United Kingdom Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 69. Netherlands Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 70. Netherlands Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 71. Netherlands Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 72. Rest of Europe Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 73. Rest of Europe Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 74. Rest of Europe Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 75. MEA Biolistic Particle Delivery System, by Country USD Million (2016-2021)
  • Table 76. MEA Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 77. MEA Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 78. MEA Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 79. Middle East Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 80. Middle East Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 81. Middle East Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 82. Africa Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 83. Africa Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 84. Africa Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 85. North America Biolistic Particle Delivery System, by Country USD Million (2016-2021)
  • Table 86. North America Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 87. North America Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 88. North America Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 89. United States Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 90. United States Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 91. United States Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 92. Canada Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 93. Canada Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 94. Canada Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 95. Mexico Biolistic Particle Delivery System, by Application USD Million (2016-2021)
  • Table 96. Mexico Biolistic Particle Delivery System, by Modality USD Million (2016-2021)
  • Table 97. Mexico Biolistic Particle Delivery System, by End User USD Million (2016-2021)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Biolistic Particle Delivery System: by Application(USD Million)
  • Table 108. Biolistic Particle Delivery System Genetic vaccination , by Region USD Million (2022-2027)
  • Table 109. Biolistic Particle Delivery System Cancer gene therapy , by Region USD Million (2022-2027)
  • Table 110. Biolistic Particle Delivery System Immunomodulation , by Region USD Million (2022-2027)
  • Table 111. Biolistic Particle Delivery System Genetic pharmacology , by Region USD Million (2022-2027)
  • Table 112. Biolistic Particle Delivery System Others , by Region USD Million (2022-2027)
  • Table 113. Biolistic Particle Delivery System: by Modality(USD Million)
  • Table 114. Biolistic Particle Delivery System Portable , by Region USD Million (2022-2027)
  • Table 115. Biolistic Particle Delivery System Fixed , by Region USD Million (2022-2027)
  • Table 116. Biolistic Particle Delivery System: by End User(USD Million)
  • Table 117. Biolistic Particle Delivery System Hospitals , by Region USD Million (2022-2027)
  • Table 118. Biolistic Particle Delivery System Genetic Research Institutes , by Region USD Million (2022-2027)
  • Table 119. Biolistic Particle Delivery System Specialty Clinics , by Region USD Million (2022-2027)
  • Table 120. Biolistic Particle Delivery System Others , by Region USD Million (2022-2027)
  • Table 121. South America Biolistic Particle Delivery System, by Country USD Million (2022-2027)
  • Table 122. South America Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 123. South America Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 124. South America Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 125. Brazil Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 126. Brazil Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 127. Brazil Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 128. Argentina Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 129. Argentina Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 130. Argentina Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 131. Rest of South America Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 132. Rest of South America Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 133. Rest of South America Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 134. Asia Pacific Biolistic Particle Delivery System, by Country USD Million (2022-2027)
  • Table 135. Asia Pacific Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 136. Asia Pacific Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 137. Asia Pacific Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 138. China Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 139. China Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 140. China Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 141. Japan Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 142. Japan Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 143. Japan Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 144. India Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 145. India Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 146. India Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 147. South Korea Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 148. South Korea Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 149. South Korea Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 150. Taiwan Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 151. Taiwan Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 152. Taiwan Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 153. Australia Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 154. Australia Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 155. Australia Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 157. Rest of Asia-Pacific Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 158. Rest of Asia-Pacific Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 159. Europe Biolistic Particle Delivery System, by Country USD Million (2022-2027)
  • Table 160. Europe Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 161. Europe Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 162. Europe Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 163. Germany Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 164. Germany Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 165. Germany Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 166. France Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 167. France Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 168. France Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 169. Italy Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 170. Italy Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 171. Italy Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 172. United Kingdom Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 173. United Kingdom Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 174. United Kingdom Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 175. Netherlands Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 176. Netherlands Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 177. Netherlands Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 178. Rest of Europe Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 179. Rest of Europe Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 180. Rest of Europe Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 181. MEA Biolistic Particle Delivery System, by Country USD Million (2022-2027)
  • Table 182. MEA Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 183. MEA Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 184. MEA Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 185. Middle East Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 186. Middle East Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 187. Middle East Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 188. Africa Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 189. Africa Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 190. Africa Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 191. North America Biolistic Particle Delivery System, by Country USD Million (2022-2027)
  • Table 192. North America Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 193. North America Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 194. North America Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 195. United States Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 196. United States Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 197. United States Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 198. Canada Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 199. Canada Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 200. Canada Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 201. Mexico Biolistic Particle Delivery System, by Application USD Million (2022-2027)
  • Table 202. Mexico Biolistic Particle Delivery System, by Modality USD Million (2022-2027)
  • Table 203. Mexico Biolistic Particle Delivery System, by End User USD Million (2022-2027)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biolistic Particle Delivery System: by Application USD Million (2016-2021)
  • Figure 5. Global Biolistic Particle Delivery System: by Modality USD Million (2016-2021)
  • Figure 6. Global Biolistic Particle Delivery System: by End User USD Million (2016-2021)
  • Figure 7. South America Biolistic Particle Delivery System Share (%), by Country
  • Figure 8. Asia Pacific Biolistic Particle Delivery System Share (%), by Country
  • Figure 9. Europe Biolistic Particle Delivery System Share (%), by Country
  • Figure 10. MEA Biolistic Particle Delivery System Share (%), by Country
  • Figure 11. North America Biolistic Particle Delivery System Share (%), by Country
  • Figure 12. Global Biolistic Particle Delivery System share by Players 2021 (%)
  • Figure 13. Global Biolistic Particle Delivery System share by Players (Top 3) 2021(%)
  • Figure 14. Global Biolistic Particle Delivery System share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2021
  • Figure 18. Chintek Technology Co., Ltd. (Taiwan) Revenue, Net Income and Gross profit
  • Figure 19. Chintek Technology Co., Ltd. (Taiwan) Revenue: by Geography 2021
  • Figure 20. Thermo Fisher Scientific, Inc. Revenue, Net Income and Gross profit
  • Figure 21. Thermo Fisher Scientific, Inc. Revenue: by Geography 2021
  • Figure 22. Wealtech Corporation Revenue, Net Income and Gross profit
  • Figure 23. Wealtech Corporation Revenue: by Geography 2021
  • Figure 24. Life Technologies Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 25. Life Technologies Corporation (United States) Revenue: by Geography 2021
  • Figure 26. Harvard Bioscience, Inc. Revenue, Net Income and Gross profit
  • Figure 27. Harvard Bioscience, Inc. Revenue: by Geography 2021
  • Figure 28. DuPont de Nemours, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. DuPont de Nemours, Inc. (United States) Revenue: by Geography 2021
  • Figure 30. Ningbo Scientz Biotechnology Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 31. Ningbo Scientz Biotechnology Co., Ltd. (China) Revenue: by Geography 2021
  • Figure 32. Biotechnologies, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 33. Biotechnologies, Inc. (India) Revenue: by Geography 2021
  • Figure 34. Global Biolistic Particle Delivery System: by Application USD Million (2022-2027)
  • Figure 35. Global Biolistic Particle Delivery System: by Modality USD Million (2022-2027)
  • Figure 36. Global Biolistic Particle Delivery System: by End User USD Million (2022-2027)
  • Figure 37. South America Biolistic Particle Delivery System Share (%), by Country
  • Figure 38. Asia Pacific Biolistic Particle Delivery System Share (%), by Country
  • Figure 39. Europe Biolistic Particle Delivery System Share (%), by Country
  • Figure 40. MEA Biolistic Particle Delivery System Share (%), by Country
  • Figure 41. North America Biolistic Particle Delivery System Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bio-Rad Laboratories, Inc. (United States)
  • Chintek Technology Co., Ltd. (Taiwan)
  • Thermo Fisher Scientific, Inc.
  • Wealtech Corporation
  • Life Technologies Corporation (United States)
  • Harvard Bioscience, Inc.
  • DuPont de Nemours, Inc. (United States)
  • Ningbo Scientz Biotechnology Co., Ltd. (China)
  • Biotechnologies, Inc. (India)
Select User Access Type

Key Highlights of Report


Jun 2022 178 Pages 50 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biolistic Particle Delivery System Market Quantitative research analysis
Global Biolistic Particle Delivery System Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rise in the Prevalence of Genetic Disorders " is seen as one of major growth factors of Biolistic Particle Delivery System Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Biolistic Particle Delivery System Market in coming years.

Know More About Global Biolistic Particle Delivery System Market Report?

Have a Query? Click Here

Other Related Reports

Pertussis Vaccines Comprehensive Study by Type (Whole-Cell Vaccines, A-Cellular Vaccines), Application (Pediatrics, Adults), Vaccine Type (DTaP (Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Qu...
$ 3450
Body Plethysmography Comprehensive Study by Type (Whole Body, Part of Body), Application (Adults, Kids), End-User (Hospitals, Fitness centers, Academic & Research centres, Others) Players and Region ...
$ 3500
Bispecific Antibodies Comprehensive Study by Type (Trifunctional Antibodies, Chemically Linked Fabs, Bispecific T Cell Engagers (BiTEs).), Application (Hospitals, Diagnostic Centers, Academic and Res...
$ 3750
Automated Gram Stainer Comprehensive Study by Application (In-house Research, Commercial Research, Clinical Diagnosis), Slide Capacity (Upto 12 Slide, 13 - 30 slides, 31 -50 slides, Above 50 slides),...
$ 3650
Cellular Therapy in Oncology Comprehensive Study by Type (Consumables, Equipment (Cell Processing Equipment, Single-use Equipment), Systems & Software), Technology (Bioreactor, Cell Immortalization T...
$ 3750
Tissue Engineering and Organ Regeneration Comprehensive Study by Type (Tissue-engineered Products, Cell Therapies (Autologous Therapies, Allogenic Therapies), Gene Therapies, Progenitor & Stem Cell T...
$ 3650